Remibrutinib: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Remibrutinib. Educational only — not medical advice.
Labeled uses
RHAPSIDO® is indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients who remain symptomatic despite H1 antihistamine treatment. Limitations of Use: RHAPSIDO is not indicated for other forms of urticaria.
Source: FDA labeling via NIH DailyMed (set e5e89bff…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.